WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Dr. Parthasaradhi, Dr. Mehruq Fatima, Syeda Fareha Fatima*, Umme Salma, Nabeela Fathima


Background: Chronic kidney disease population can be distinguished by its vulnerability as it is associated with multiple concurrent comorbidities requiring the use of numerous medications, ensuing intricate therapeutic regimens, intermittent medication modifications and restricted lifestyles resulting in a substantial risk for developing actual and potential drug-related problems (DRPs) which are associated with significant morbidity, mortality, and cost. Aim: To evaluate the drug therapy regimens of CKD stage (3-5) patients for determining the prevalence and identifying the types of DRPs. Methods: Prospective observational 6-month study was conducted in CKD (stage3-5) patients who were aged > 18 years and admitted in owaisi hospital and research centre. Patients' data and drug therapies were collected through direct patient interview, discussion with nursing staff, assessment of patients' medication charts and medical records. DRPs were identified and classified into 6 main categories (according to The PCNE V 5.01). Descriptive analysis was done for demographic data, comorbidities, drug utilization, and DRPs' profiles and Pearson's correlation test was used to assess the correlation between drugs and DRPs. Results: Out of 30 patients in the study, 26 had DRPs. A total of 79 DRPs were identified with an average of 2.63 + 2.0 DRPs per subject. Of which, 53.16% were actual DRPs and 46.83% were potential DRPs. Drug interactions (48.10%) and adverse drug reactions (29.11%) were found to be the major DRPs followed by Drug choice problem (11.39%), Dosing problem (10.12%), Other DRPs (1.26%) and Drug use problem (0%) respectively. Conclusion: Our study reveals that DRPs among the CKD (stage3-5) patients were high. Drug interactions and adverse drug reactions contributed to the majority of DRPs identified. Timely appropriate monitoring, prevention, identification and resolution of DRPs are crucial to optimize clinical outcomes in CKD patients.

Keywords: Drug-Related Problems, Chronic Kidney Disease, PCNE, Adverse reactions, drug interactions, dosing problems.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More